Delving into the Latest Updates on Multipeptide Vaccine(University Hospital Tuebingen) with Synapse

Overview

Basic Info

Drug Type

Synthetic peptide vaccine, Therapeutic vaccine

Synonyms

Multi-peptide Vaccination Adjuvanted With the TLR1/2 Ligand XS15

Target-

Action

stimulants

Mechanism

Immunostimulants

Therapeutic Areas

NeoplasmsImmune System DiseasesNervous System Diseases+ [2]

Active Indication

Adult Acute Myeloblastic LeukemiaGlioblastoma MultiformeChronic Lymphocytic Leukemia

Inactive Indication-

Originator Organization

University Hospital Tübingen

Active Organization

University Hospital Tübingen

Inactive Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

The aim of this Phase I study is to evaluate the immunogenicity along with safety and toxicity as well as first efficacy of a multi-peptide vaccine adjuvanted with the TLR1/2 ligand XS15 emulsified in Montanide ISA 51 VG (AML-VAC-XS15) in AML patients who have achieved CR or CRi with first line treatment.

Start Date02 May 2024

Sponsor / Collaborator

University Hospital Tübingen

NCT04842513

/ CompletedPhase 1IIT

Multi Peptide Vaccination with Pam3Cys-GDPKHPKSF (XS15) As an Immunomodulator in Addition to Standard Postoperative Radiation Therapy and Temozolomide Chemotherapy in Newly Diagnosed HLA-A2-positive MGMT-methylated Glioblastoma

Newly diagnosed HLA-A2-positive MGMT-methylated glioblastoma patients will be vaccinated with a Multi peptide vaccination with Pam3Cys-GDPKHPKSF (XS15) as an immunomodulator in addition to standard postoperative radiation therapy and temozolomide chemotherapy to assess immunogenicity, efficacy, safety of the combination of multipeptide vaccination and the immune modulator XS15 emulsified in Montanide ISA 51 VG

Start Date03 May 2021

Sponsor / Collaborator

University Hospital Tübingen

NCT04688385

/ CompletedPhase 1IIT

IVAC-XS15-CLL01: Personalized Multi-peptide Vaccination in Combination with the TLR1/2 Ligand XS15 in CLL Patients Undergoing Ibrutinib-based Regimes

The aim of this study is to evaluate the efficiency along with safety and toxicity of a personalizied multi-peptide vaccine in combination with the TLR1/2 ligand XS15 in CLL patients undergoing ibrutinib-based regimes.

Start Date23 Dec 2020

Sponsor / Collaborator

University Hospital Tübingen

100 Clinical Results associated with Multipeptide Vaccine(University Hospital Tuebingen)

Login to view more data

100 Translational Medicine associated with Multipeptide Vaccine(University Hospital Tuebingen)

Login to view more data

100 Patents (Medical) associated with Multipeptide Vaccine(University Hospital Tuebingen)

Login to view more data

100 Deals associated with Multipeptide Vaccine(University Hospital Tuebingen)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Adult Acute Myeloblastic Leukemia	Phase 1	-	University Hospital Tübingen	02 May 2024
Glioblastoma Multiforme	Phase 1	Germany	University Hospital Tübingen	03 May 2021
Chronic Lymphocytic Leukemia	Phase 1	Germany	University Hospital Tübingen	23 Dec 2020